51 results about "Gallbladder cancer" patented technology

The invention discloses a magnetic resonance guided focusing microwave brain tumor thermal ablation system and a focusing adjustment method. According to the invention, three-dimensional data of MRI and CT are integrated, microwave frequency suitable for tumor size and depth is selected, and an appropriate antenna and cross polarized antenna phased array is designed. The output power and phase of the antenna are optimized by using a differential evolution algorithm, accurate focusing of microwave energy is realized, the tumor temperature is increased to an ablation level, and meanwhile, the safe temperature of healthy tissues is kept. The system effectively inhibits adverse effects of brain tissues including skull on microwave penetration, and realizes accurate ablation of tumors through combination of a small number of antennas and an iterative algorithm. MRI guidance and real-time temperature monitoring are combined, so that the accuracy and safety of thermal ablation are ensured, the brain tumor is radically treated in a non-invasive manner, and the problem that the medicine cannot penetrate through the blood brain barrier is solved. In addition, the technology can also be used for treating liver cancer, pancreatic cancer, thyroid cancer, breast cancer, kidney cancer, bone cancer, bladder cancer, gallbladder cancer and other diseases.

The invention discloses a gallbladder malignant tumor protein diagnosis biomarker combination, a kit and application. The protein marker provided by the invention comprises CA1 and / or IGFBP6 (insulin-like growth factor binding protein 6). According to the invention, an LC-MS / MS mass spectrometry method is adopted, mass spectrometry is carried out on a large number of clinical plasma samples, and by calculating log2 difference multiples of corresponding protein molecule contents in the plasma of a gallbladder cancer patient and the plasma of a normal person, it is determined that two protein molecules (CA1 protein and IGFBP6 protein) have good inspection benefits; the kit can be used as a marker for early diagnosis of gallbladder cancer; therefore, the invention provides a non-invasive screening means based on plasma, and the non-invasive screening means is used for predicting the cholecystic malignant tumor and distinguishing the cholecystic carcinoma crowd from the non-cancer crowd. And materials are convenient to take, the blood sample amount is small, and the sensitivity is high. The invention can fill the blank that no protein marker combination with high diagnostic efficiency exists at present for the cholecystic malignant tumor, and has great clinical significance.

Abstract The present invention provides antibodies useful as therapeutics for treating and / or preventing diseases associated with cells expressing CLD18, including tumor-related diseases such as gastric cancer, esophageal cancer, pancreatic cancer, lung cancer, ovarian cancer, hepatic cancer, head-neck cancer, and cancer of the gallbladder. 2020220128 20 Aug 2020

The invention relates to the technical field of antibodies, in particular to an anti-human OLFM4 neutralizing monoclonal antibody and application thereof in treating gallbladder cancer. The invention provides two different cloned anti-human OLFM4 neutralizing monoclonal antibodies and provides amino acid sequence information of the monoclonal antibodies, the OLFM4 monoclonal antibodies have the functions of inhibiting growth, invasion and progress of gallbladder cancer, and a new thought is provided for clinical targeted therapy of gallbladder cancer patients.

The application finds that SDF4 in a body fluid sample can become a marker for detecting cancer patients with good sensitivity and specificity. By using a reagent for specifically detecting SDF4, gastric cancer, breast cancer, colorectal cancer, pancreatic cancer, esophageal cancer, liver cancer, liposarcoma, bladder cancer, brain tumor, head and neck cancer, gallbladder cancer, ovarian cancer, tongue cancer, or uterine cancer can be detected. The measurement of SDF4 in a body fluid sample is a detection method capable of detecting various cancers by a single test, and can be used for large-scale screening of cancers. In addition, early-stage cancers can be detected with good sensitivity and specificity, so that cancers can be found and treated in an early stage.

It has been found that SDF4 in a body fluid sample can be a marker for detecting a cancer patient with good sensitivity and specificity. Gastric cancer, breast cancer, colorectal cancer, pancreatic cancer, esophageal cancer, hepatic cancer, liposarcoma, bladder cancer, brain tumor, head and neck cancer, gallbladder cancer, ovarian cancer, tongue cancer, or uterine cancer can be detected by using a reagent that specifically detects the SDF4. The measurement of the SDF4 in the body fluid sample is an examination method capable of detecting various types of cancer with a single examination, and can be used for mass screening for cancer. Moreover, early-stage cancer can also be detected with good sensitivity and specificity, and thus cancer can be discovered at an early stage, leading to treatment.

The invention provides a gallbladder cancer prediction method and device based on plasma free DNA mutation detection. The gallbladder cancer prediction method comprises the steps that a gene mutation feature extraction module extracts sample gene mutation features from sample gene sequencing data through a gene mutation analysis algorithm; the gall bladder occupying benign and malignant identification model building module is used for screening key genes of gallbladder cancer from the target genes based on gene mutation characteristics so as to obtain a trained gall bladder occupying benign and malignant identification model; the detection module obtains gene mutation characteristics of key genes of a to-be-detected person from plasma free DNA of the to-be-detected person, and inputs the gene mutation characteristics of the key genes of the to-be-detected person into the gallbladder occupation benign and malignant identification model to obtain the malignant probability of gallbladder occupation lesion. According to the method, the peripheral blood of a patient can be collected in a non-invasive mode, free DNA is extracted, harm and pain to the patient are reduced, and a judgment result containing the prediction probability of the gallbladder cancer can be accurately and efficiently obtained through the gallbladder occupation benign and malignant identification model.

The invention discloses a human gallbladder cancer cell line and application thereof. The human gall bladder cancer cell line comprises a human gall bladder cancer cell JXQ-3D-8529R1 or a human gall bladder cancer cell JXQ-3D-8529R2; the human gallbladder cancer cell JXQ-3D-8529R1 is preserved in the China Center for Type Culture Collection, and the preservation number of the human gallbladder cancer cell JXQ-3D-8529R1 is CCTCC NO: C2023372; the preservation number of the human gallbladder cancer cell JXQ-3D-8529R2 is CCTCC (China Center For Type Culture Collection) NO: C2023371. The human gallbladder cancer cells JXQ-3D-8529R1 and JXQ-3D-8529R2 can be massively amplified, can be subcultured in vitro for a long time, have different sensitivities to cis-platinum, gemcitabine and the like, enrich a human gallbladder cancer cell bank, and provide a new test material for revealing the occurrence and development mechanism of gallbladder cancer and preclinical research of corresponding drug development.

The invention discloses an application of a compound as a CYP2E1 inhibitor, which is characterized in that the compound or a salt thereof as an inhibitor takes CYP2E1 as a target spot and is combined with the CYP2E1, and the CYP2E1 inhibitor has an inhibition effect on CYP2E1. The inhibitor can be used for preventing and treating tumors such as liver cancer, glioma, ovarian cancer, bladder cancer and gallbladder cancer. Similarly, the inhibitor can also be used for preventing and treating other inflammation-related diseases such as liver injury, fatty liver, hepatitis, hepatic fibrosis, rheumatic and rheumatoid arthritis, sepsis, Alzheimer's disease, ischemic cerebral apoplexy, Parkinson's disease, hyperlipidemia, atherosclerosis, coronary heart disease, diabetes mellitus and the like.

The invention relates to the field of biological medicines, and discloses a preparation method and application of a neutralizing antibody capable of effectively inhibiting dryness of gallbladder cancer cells and progress of gallbladder cancer and remarkably improving the lifetime and prognosis of a patient. A gene sequence for coding the humanized anti-FZD6 monoclonal neutralizing antibody comprises a sequence of a heavy chain variable region and a sequence of a light chain variable region. The gene sequence of the heavy chain variable region is as shown in SEQ ID NO: 1, and the gene sequence of the light chain variable region is as shown in SEQ ID NO: 2. The neutralizing antibody targets a non-classical Wnt pathway receptor FZD6, so that the activation of a Wnt / Ca < 2 + > signal pathway can be effectively inhibited, and the migration and growth of gallbladder tumor cells can be inhibited. Experimental detection proves that the FZD6 neutralizing antibody can effectively block the interaction between Wnt5a-FZD6-mediated tumor-related fibroblasts and gallbladder cancer cells, remodel the gallbladder cancer immunosuppressive tumor microenvironment and inhibit the dryness of gallbladder tumor cells and the migration and growth of gallbladder cancer cells, and can be applied to preparation of gallbladder cancer specific targeting drugs.

The invention relates to the field of biological medicines, and discloses a targeted inhibitor capable of effectively inhibiting the progress of gallbladder cancer and remarkably improving the lifetime and prognosis of a patient. Through single-cell transcriptome data of a gallbladder cancer patient, single-cell transcriptome data of gallbladder cancer organoid, multiple immunofluorescence experiments, real-time quantitative PCR of gallbladder cancer cell lines, immunohistochemistry of gallbladder cancer tissues and organoid, gallbladder cancer whole exon data and inhibitor agonist experiments, it is found that compared with para-carcinoma, the single-cell transcriptome data of the gallbladder cancer patient, the single-cell transcriptome data of the gallbladder cancer organoid, the single-cell Differential genes of gallbladder cancer epithelial cells in cancer tissues are enriched to a WNT pathway, crosstalk is generated between the gallbladder cancer epithelial cells mainly through a WNT7A-FZD6 ligand and receptor pair in a WNT signal pathway, and inflammatory fibroblasts and epithelial cells can perform intercellular communication through a WNT5A-FZD6 ligand and receptor pair in an ncWNT signal pathway.

This invention discloses a method for fabricating a memristor based on a bile functional layer, belonging to the field of bioelectronic device fabrication and in vitro diagnostics of biliary tract diseases. The method sequentially completes FTO substrate pretreatment, bile functional layer preparation, Ag-on-electrode deposition, and memristor detection array fabrication. First, the FTO substrate is physically cleaned and plasma-activated. Then, a 240-260 nm bile functional layer is prepared. Subsequently, an Ag-on-electrode is deposited, and a 5-15 nm Ag atom embedding transition region is constructed. Finally, a 2×2 array is arranged and passivated for isolation. The process parameters of each step are synergistically matched to optimize the interface between the substrate, functional layer, and electrode, fully preserving bile pathological information. The resulting Ag / Bile / FTO structure memristor exhibits high electrical stability and shows significant differences in electrical response to bile samples from normal, gallstone, and gallbladder cancer patients. It enables accurate and rapid in vitro identification of biliary tract diseases, and the process is simple, low-cost, and suitable for clinical application and large-scale production.

Compositions and methods of making isolated binding molecules (e.g., antibodies) or antigen-binding fragments thereof that can be used as therapeutic agents to treat and / or prevent diseases associated with cells expressing intimate junction protein 18.2, including tumor-associated diseases, such as tumor-associated diseases, tumor-associated diseases, tumor-associated diseases, tumor-associated diseases, tumor-associated diseases, tumor-associated diseases, tumor-associated diseases, tumor-associated diseases, tumor-associated diseases, tumor-associated diseases, tumor-associated diseases, such as gastric cancer, esophageal cancer, pancreatic cancer, lung cancer, ovarian cancer, colon cancer, liver cancer, head and neck cancer and gallbladder cancer. Also described are pharmaceutical formulations comprising the composition for the treatment of disease, as a single agent (e.g., a naked antibody), or as an adjuvant therapy of other antigen-binding anti-cancer agents such as immune checkpoint inhibitors (e.g., anti-CTLA-4 and anti-PD-1 / PD-L1 monoclonal antibodies), and / or as a combination therapy, e.g., anti-CTLA-4 and anti-PD-1 / PD-L1 monoclonal antibodies). Wherein the anti-tight junction protein 18.2 antibody is administered prior to, after, or concurrently with chemotherapy.

The application relates to the field of biological medicines, and particularly relates to a long-chain non-coding RNA (lncRNA) encoded short peptide and corresponding monoclonal antibody, the short peptide is encoded by long-chain non-coding RNA LOXL1-AS1 and is named PEPLA, research shows that PEPLA is highly specifically expressed in gallbladder cancer tissues and has a significant difference compared with normal tissues, based on this, a recombinant expression method of PEPLA is provided, and a monoclonal antibody taking PEPLA as an antigen is constructed, the monoclonal antibody can specifically recognize PEPLA, and is further applied to the diagnosis, prognosis evaluation and targeted treatment of gallbladder cancer, the technology provides a new molecular target for early diagnosis and precise treatment of gallbladder cancer, and has a wide clinical application prospect.

This application discloses the application of PLAC8 as a target in the preparation of tumor therapeutic drugs, involving the field of biomedical technology. This application clarifies that the "sympathetic nervous system-β2-AR-PLAC8-cholesterol metabolism-M2 polarization" pathway is the core driving pathway for stress-related tumor progression and chemotherapy resistance. It reveals the molecular mechanism by which PLAC8 inhibits cholesterol synthesis through phosphorylation at the S67 site, binding to the N-terminal domain of SREBP2, recruiting OGT to mediate SREBP2O-GlcNAc glycosylation. Through strategies such as gene silencing, β2-AR antagonist intervention, and targeted delivery of siPLAC8 via mannose-modified lipid nanoparticles (LNPs), the application achieved the effects of inhibiting M2 macrophage accumulation, inhibiting tumor growth, and reversing chemotherapy resistance in various tumor models, including gallbladder cancer, intrahepatic cholangiocarcinoma, and prostate cancer. Furthermore, the LNPs delivery system showed no significant toxicity. This research provides a novel therapeutic target centered on PLAC8 and a safe and effective targeted intervention strategy for stress-related tumors, highlighting its clinical translational value.

The present invention relates to the field of medical technology and is a method for preparing an ultrasensitive electrochemical immunosensor for specifically detecting CTCs in gallbladder cancer. The method comprises the following steps: a. synthesizing SiO2 nanospheres; b. synthesizing SiO2@QD using the SiO2 nanospheres synthesized in step a; c. preparing SiO2@QD-Ab using the SiO2@QD synthesized in step b; and d. constructing an immunoelectrochemical platform using the SiO2@QD-Ab synthesized in step c. The present invention also discloses a method for applying the ultrasensitive electrochemical immunosensor for specifically detecting CTCs in gallbladder cancer. The method exhibits high sensitivity, high specificity, low cost, and rapid detection speed.

The invention discloses an application of a compound as a CYP2E1 inhibitor, which is characterized in that the compound or a salt thereof as an inhibitor takes CYP2E1 as a target spot and is combined with the CYP2E1, and the CYP2E1 inhibitor has an inhibition effect on CYP2E1. The inhibitor can be used for preventing and treating tumors such as liver cancer, glioma, ovarian cancer, bladder cancer and gallbladder cancer. Similarly, the inhibitor can also be used for preventing and treating other inflammation-related diseases such as liver injury, fatty liver, hepatitis, hepatic fibrosis, rheumatic and rheumatoid arthritis, sepsis, Alzheimer's disease, ischemic cerebral apoplexy, Parkinson's disease, hyperlipidemia, atherosclerosis, coronary heart disease, diabetes mellitus and the like.

The invention relates to the technical field of molecular biology and medical detection, and particularly discloses a group of gallbladder cancer plasma exosome microRNAs markers as well as a detection method and application of the gallbladder cancer plasma exosome microRNAs markers, and the markers comprise at least one of miR-135b-5p, miR-224-5p, miR-451a, miR-148a-3p and miR-375-3p. The marker combination shows a characteristic expression profile (two-liter and three-drop) in gallbladder cancer patients; the invention provides a non-diagnostic purpose detection method of the marker, efficient and non-invasive identification of gallbladder cancer is realized by optimizing an exosome separation and detection process and constructing a combined diagnosis model, the AUC reaches 0.987, the sensitivity is 93.3%, and the specificity is 91.7%; the marker and the method can be used for preparing a detection kit related to gallbladder cancer, and have important clinical application value.

The present application belongs to the field of biomedicine. Disclosed are an siRNA for inhibiting KRAS gene expression, and a modified form thereof and the use thereof. Provided in the present application is a double-stranded RNA molecule targeting KRAS, wherein the molecule can treat KRAS-associated diseases such as metastatic non-small cell lung cancer, metastatic pancreatic ductal adenocarcinoma, KRAS G12C+ non-small cell lung cancer, diabetic retinopathy, leukemia, cholangiocarcinoma, metastatic colorectal cancer, gastric cancer, advanced non-small cell lung cancer, stage-IV non-small cell lung cancer, gastric adenocarcinoma, sepsis, KRAS G12C-mutated advanced non-small cell lung cancer and gallbladder cancer.

The present invention discloses a magnetic resonance-guided focused microwave brain tumor thermal ablation system and a focusing adjustment method. The present invention integrates the three-dimensional data of MRI and CT, selects the microwave frequency suitable for the size and depth of the tumor, and designs a suitable antenna and a cross-polarized antenna phased array. The differential evolution algorithm is used to optimize the antenna output power and phase to achieve precise focusing of microwave energy, increase the tumor temperature to the ablation level, and maintain the safe temperature of healthy tissue. The system effectively suppresses the adverse effects of brain tissue, including the skull, on microwave penetration, and achieves precise ablation of tumors through a small number of antennas combined with an iterative algorithm. Combined with MRI guidance and real-time temperature monitoring, the accuracy and safety of thermal ablation are ensured, non-invasive radical treatment of brain tumors is achieved, and the problem of drugs being unable to penetrate the blood-brain barrier is overcome. In addition, this technology can also be used to treat other diseases such as liver cancer, pancreatic cancer, thyroid cancer, breast cancer, kidney cancer, bone cancer, bladder cancer, and gallbladder cancer.

To provide methods for effectively treating and / or preventing cancer diseases.SOLUTION: The present invention provides a combination therapy comprising an anti-Claudin (CLDN) 18.2 antibody and an immune checkpoint inhibitor for effectively treating and / or preventing diseases associated with cells expressing CLDN18.2, including cancer diseases such as gastric cancer, esophageal cancer, pancreatic cancer, lung cancer, ovarian cancer, colon cancer, hepatic cancer, head-neck cancer, and cancer of the gallbladder and metastases thereof.SELECTED DRAWING: Figure 1

The invention discloses a human gallbladder cancer cell line and application thereof, and relates to the technical field of cells. The human gallbladder cancer cell line disclosed by the invention is named as a human gallbladder cancer cell line IIAIM-GBC021A6 Homo sapiens, the human gallbladder cancer cell line is preserved in the China Center for Type Culture Collection on February 14, 2025, and the preservation number is CCTCC (China Center for Type Culture Collection) NO: C202559. The human gallbladder cancer cell line IIAIM-GBC021A6Homo sapiens is stable in character, has strong proliferation ability, scratch healing ability, migration ability and in-vitro tumor formation ability, and has different sensitivities to different chemotherapeutic drugs such as cis-platinum, carboplatin, gemcitabine, oxaliplatin, 5-fluorouracil (5-Fu) and the like.

The invention relates to siRNA targeting TRIM29, the sequence of the siRNA is shown as SEQ ID NO.1. Through cell level and animal level experiment detection, the siRNA can inhibit expression of the TRIM29, and the sensitivity of gallbladder cancer to gemcitabine is remarkably improved; the invention further relates to gemcitabine and TRIM29 siRNA co-loaded lipid nanoparticles and a preparation method and application thereof, the preparation method comprises the steps that firstly, gemcitabine and TRIM29 siRNA wrapped lipid nanoparticles are constructed, then the gemcitabine and TRIM29 siRNA are co-incubated to obtain GSL, the GSL is oval in microcosmic shape and good in stability, through cell level and animal level experiment detection, the GSL has a good anti-tumor effect, and the GSL has a good anti-tumor effect on the gemcitabine and TRIM29 siRNA co-loaded lipid nanoparticles. The GSL can significantly reduce the protein expression level of TRIM29, significantly improve the sensitivity of gallbladder cancer to gemcitabine, inhibit tumor growth, and inhibit STAT3 pathway, and the GSL prepared by the method has good biological safety, and opens up a new channel for treatment of gallbladder cancer.

The present invention provides poly(ADP-ribose) polymerase (PARP) inhibitors, methods for preparing them, pharmaceutical compositions comprising them, and methods of using them for treating, preventing, and / or ameliorating PARP-mediated diseases or disorders. Specifically, the compounds described herein can be used to treat breast cancer, ovarian cancer, liver cancer, lung cancer, small cell lung cancer, esophageal cancer, gallbladder cancer, pancreatic cancer, and gastric cancer.

The present invention discloses the use of peripheral blood leukocyte RNA combined markers in the preparation of a kit for detecting or diagnosing early primary gallbladder cancer. The present invention is based on peripheral blood leukocyte RNA markers for detection. The marker is a liquid biopsy biomarker that is more sensitive, stable, non-invasive, and requires less sample volume, which is more acceptable to patients. Its successful development will help the diagnosis of gallbladder cancer. The etiology of primary gallbladder cancer is complex. Compared with a single molecular marker, the present invention evaluates the accuracy of the test sample from two dimensions of abnormally high expression and low expression, which can reduce the error caused by individual expression differences of a single indicator to a certain extent, making the result more accurate.

To provide a combination therapy for effectively treating and / or preventing diseases associated with cells expressing CLDN18.2.SOLUTION: The present invention provides a combination therapy for effectively treating and / or preventing diseases associated with cells expressing CLDN18.2, including cancer diseases such as gastric cancer, esophageal cancer, pancreatic cancer, lung cancer, ovarian cancer, colon cancer, hepatic cancer, head and neck cancer, and cancer of the gallbladder and metastases thereof.SELECTED DRAWING: None

The application discloses a histone deacetylase 6 inhibitor and application thereof, and belongs to the technical field of chemical medicines. The inhibitor is the following compound or pharmaceutically acceptable salt thereof: which can be used for the treatment of lung cancer, melanoma, liver cancer, kidney cancer, leukemia, non-small cell lung cancer, prostate cancer, thyroid cancer, skin cancer, pancreatic cancer, ovarian cancer, testicular cancer, breast cancer, bladder cancer, gallbladder cancer, myelodysplastic syndrome, lymphoma, esophageal cancer, thyroid follicular cancer, gastrointestinal cancer, tumors of the central or peripheral nervous system, mesothelioma, type II or non-insulin-dependent diabetes, and autoimmune diseases.

The invention belongs to the field of biological pharmacy, and particularly discloses application of evodiamine in inhibition of migration and invasion of gallbladder cancer cells and metastatic tumor growth. Aiming at the problems of poor drug targeting, high toxicity, easy drug resistance and the like in gallbladder cancer hepatic metastasis treatment, the invention provides various application forms of evodiamine: 1) an evodiamine single-drug sustained release preparation (PLGA or chitosan carrier) realizes long-acting sustained release through local intervention or intratumor injection; 2) the evodiamine liposome preparation (the ratio of DPPC to cholesterol is 3: 1, and the particle size is 80-150nm) can improve the enrichment rate of hepatic metastatic focus to 5.8% or above; (3) the evodiamine and chemotherapeutic drugs (oxaliplatin, 5-FU and the like) are combined to form a composition, and the synergy index is Cilt; 0.8, the toxicity of the system is obviously reduced; animal experiments show that the liver metastasis inhibition rate reaches 82.7% and the weight loss rate is only 10.5% when the liposome (3 mg / kg of evodiamine and 6 mg / kg of oxaliplatin) is combined, and a high-efficiency and low-toxicity solution is provided for gallbladder carcinoma metastasis.

A compound represented by Formula 1, a stereoisomer thereof or a pharmaceutically acceptable salt thereof may be used for treating or preventing an autoimmune disease or a cancer. The autoimmune disease may be any one selected from the group consisting of inflammatory bowel disease, multiple sclerosis, graft-versus-host disease, asthma, atopy, psoriasis, rheumatoid arthritis, systemic lupus erythematous and type 1 diabetes. The cancer may be selected from the group consisting of colon cancer, melanoma, liver cancer, gliocytoma, ovarian cancer, colorectal cancer, head and neck cancer, bladder cancer, kidney cell cancer, stomach cancer, breast cancer, metastatic cancer, prostate cancer, gallbladder cancer, pancreatic cancer, blood cancer, skin cancer and lung cancer.